Abstract
In the dexamethasone-treated rat model of cryptosporidiosis, paromomycin was effective at a dosage of 50 mg/kg/day or more for ileal infection and 200 mg/kg/day or more for cecal infection. At 1 and 3 weeks after treatment, a persistent infection was demonstrated in all rats. These results confirm the anticryptosporidial activity of paromomycin and underscore the limitations of this compound because of its potential toxicity at such high dosages and its inability to eradicate the infection.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Bacterial Agents / adverse effects
-
Anti-Bacterial Agents / therapeutic use*
-
Cryptosporidiosis / drug therapy*
-
Cryptosporidiosis / parasitology
-
Cryptosporidium parvum*
-
Dexamethasone / pharmacology*
-
Feces / microbiology
-
Female
-
Immunosuppressive Agents / pharmacology*
-
Mice
-
Mice, Inbred BALB C
-
Paromomycin / adverse effects
-
Paromomycin / therapeutic use*
-
Rats
-
Rats, Sprague-Dawley
Substances
-
Anti-Bacterial Agents
-
Immunosuppressive Agents
-
Paromomycin
-
Dexamethasone